Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study

(2015) Claudia Lundgren et al.   ACTA ONCOLOGICA

Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

(2015) Jonathan D Black et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Abstract 1650: CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations

(2015) Chiara Saladino et al.   CANCER RESEARCH

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2015) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

Abstract B182: Molecular basis for clinical development of the novel CDK2/9 inhibitor CYC065 in oncology

(2015) Craig MacKay et al.   MOLECULAR CANCER THERAPEUTICS

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

(2015) S. Lopez et al.   MOLECULAR CANCER THERAPEUTICS

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Targeted therapy in the treatment of uterine serous carcinoma

(2015) Carlton L Schwab et al.   PHARMACOGENOMICS

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression

(2015) Liu Yang et al.   Oncotarget

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

(2015) Barbie Taylor-Harding et al.   Oncotarget

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo

(2014) Carlton L. Schwab et al.   GYNECOLOGIC ONCOLOGY

Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo

(2014) Salvatore Lopez et al.   GYNECOLOGIC ONCOLOGY

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)

(2013) Diana P. English et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer

(2013) D. Etemadmoghadam et al.   CLINICAL CANCER RESEARCH

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

(2013) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma

(2013) Elisabetta Kuhn et al.   MODERN PATHOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

(2013) S. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses

(2012) Elisabetta Kuhn et al.   JNCI-Journal of the National Cancer Institute

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Uterine Papillary Serous Carcinoma

(2011) KATHLEEN N. MOORE et al.   CLINICAL OBSTETRICS AND GYNECOLOGY

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients

(2011) Maurizio Scaltriti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

(2010) Christophe Le Tourneau et al.   EUROPEAN JOURNAL OF CANCER

Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer

(2010) Dariush Etemadmoghadam et al.   PLoS One

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH